Now Playing
|Videos|December 20, 2022
Expert Perspectives on Novel Drug Delivery Systems in the Management of Pediatric ADHD
Author(s)Jeffrey L Alvaro, MD
Jeffrey L. Alvaro, M.D., introduces an upcoming panel discussion surrounding the clinical implications of novel drug delivery systems in the management of Pediatric ADHD, utilizing 3 patient cases.
Advertisement
Episodes in this series
Advertisement
Related to this article
Learn how to distinguish true ADHD from anxiety, trauma, sleep issues, or substance use by tracing symptoms back to childhood across settings and impairment.
NHIS data show the share of US children aged 5 to 17 years ever diagnosed with ADHD climbed from 9.9% in 2019 to 13.8% in 2025.
Self-harm risk in ADHD peaked in the 90 days before medication initiation and declined once treatment began, a 5-system analysis found.
Lower maternal PlGF in the third trimester was tied to child ADHD in a University of Iowa cohort, independent of preeclampsia and FGR.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Skipping newborn vitamin K tied to 47% higher infant bleeding risk
2
Breastfeeding essentials: Assessing latch and milk transfer
3
Contemporary Pediatrics week in review: November 2-6, 2026
4
Maternal RSVpreF 78% effective against infant RSV hospitalization
5